Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 5:49 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 144 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Short Bowel Clear all
Terminated Phase 2 Interventional Results available

Pre- and Post-operative FOLFOX Based Therapy for Patients With Colorectal Cancer With Liver Involvement

NCT00537823
View directory record Official record
Conditions
Colorectal Cancer, Metastases
Interventions
Cetuximab, Bevacizumab, Leucovorin, Oxaliplatin, Fluorouracil
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Dec 19, 2016 · Synced Jul 22, 2026, 5:49 AM EDT
Enrolling by invitation Not applicable Interventional Accepts healthy volunteers

Palliative Care Needs of Children With Rare Diseases and Their Families

NCT06938542
View directory record Official record
Conditions
Trisomy 13 Syndrome, Arthrogryposis Congenita Multiplex With Intestinal Atresia, Asparagine Synthetase Deficiency, CHARGE Syndrome, Early Infantile Epileptic Encephalopathy, FOXG1 Syndrome, KBG Syndrome, Noonan Syndrome, Severe Hemophilia A, Short Bowel Syndrome, Beta-Propeller Protein-Associated Neurodegeneration, Brain Injury of Prematurity With Periventricular Leukomalacia, Chromosome 17p13.3 Microdeletion Syndrome, Chromosome 1q43-1q44 Deletion, Cockayne Syndrome, Congenital Diaphragmatic Hernia, End-Stage Renal Disease With Cloacal Anomaly, Mitochondrial Depletion Disorder, Severe Factor VII Deficiency
Interventions
Family Centered pediatric palliative care for family caregivers of children with rare diseases.
Behavioral
Lead sponsor
Children's National Research Institute
Other
Eligibility
12 Months to 99 Years
Enrollment
480 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2029
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jan 27, 2026 · Synced Jul 22, 2026, 5:49 AM EDT
Completed Not applicable Interventional

Home Parenteral Nutrition (HPN) Families' Mobile Distance Connections to Care Research

NCT01900288
View directory record Official record
Conditions
Short Bowel Syndrome, Malabsorption, Malnutrition
Interventions
HPN Group Clinic Appointments using Mobile Devices (experimental), Mobile Device Access (placebo)
Behavioral
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
13 Years and older
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Jan 26, 2017 · Synced Jul 22, 2026, 5:49 AM EDT
Recruiting Phase 2 Interventional

Total Neoadjuvant Therapy With mFOLFOX and Short-course Radiation in Resectable Rectal Cancer

NCT04643366
View directory record Official record
Conditions
Rectal Cancer
Interventions
Chemotherapy, Radiation Therapy
Drug · Radiation
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2032
U.S. locations
4
States / cities
Richmond, Virginia • South Hill, Virginia • Tappahannock, Virginia
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Jul 22, 2026, 5:49 AM EDT
Recruiting Phase 2 Interventional

Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer

NCT01174121
View directory record Official record
Conditions
Metastatic Colorectal Cancer, Metastatic Pancreatic Cancer, Metastatic Ovarian Cancer, Metastatic Breast Carcinoma, Metastatic Endocrine Tumors/ Neuroendocrine Tumors
Interventions
Pembrolizumab (Keytruda), Fludarabine, Cyclophosphamide, Aldesleukin, Young TIL
Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 72 Years
Enrollment
332 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2029
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Jul 22, 2026, 5:49 AM EDT
Completed Phase 3 Interventional Results available

A Pharmacokinetic, Safety, and Pharmacodynamic Study of Teduglutide in Pediatric Subjects With Short Bowel Syndrome

NCT01952080
View directory record Official record
Conditions
Short Bowel Syndrome
Interventions
teduglutide
Drug
Lead sponsor
Shire
Industry
Eligibility
1 Year to 17 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
18
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Los Angeles, California + 14 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2021 · Synced Jul 22, 2026, 5:49 AM EDT
Completed Early Phase 1 Interventional

Safety, Tolerability, and Pharmacodynamics of SYNB8802v1 in Subjects With History of Gastric Bypass Surgery or Short-bowel Syndrome

NCT05377112
View directory record Official record
Conditions
Enteric Hyperoxaluria
Interventions
SYNB8802v1, Placebo
Drug · Other
Lead sponsor
Synlogic
Industry
Eligibility
18 Years to 74 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Mar 16, 2023 · Synced Jul 22, 2026, 5:49 AM EDT
Not yet recruiting Not applicable Interventional

The Effects of Mango on Gut Health Markers

NCT07559604
View directory record Official record
Conditions
Gut Health, LBP, Short Chain Fatty Acids, sCD14
Interventions
Mango
Behavioral
Lead sponsor
Loma Linda University
Other
Eligibility
40 Years to 60 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Loma Linda, California
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Jul 22, 2026, 5:49 AM EDT
Completed Phase 4 Interventional Results available

Short Bowel Syndrome and Teduglutide Versus Placebo

NCT02099084
View directory record Official record
Conditions
Short Bowel Syndrome
Interventions
Teduglutide, Placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 75 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 21, 2016 · Synced Jul 22, 2026, 5:49 AM EDT
Not listed Phase 1Phase 2 Interventional

Proof of Concept Study in Patients With Short Bowel Syndrome

NCT04379856
View directory record Official record
Conditions
Short Bowel Syndrome
Interventions
NM-002
Drug
Lead sponsor
9 Meters Biopharma, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Nov 19, 2020 · Synced Jul 22, 2026, 5:49 AM EDT
Terminated Phase 1 Interventional Results available

Evaluation of the Safety, Tolerability, and Efficacy of MDGN-002 in Adults With Moderate to Severe Active Crohn's Disease or Ulcerative Colitis

NCT03169894
View directory record Official record
Conditions
Crohn Disease, Ulcerative Colitis
Interventions
MDGN-002
Drug
Lead sponsor
Avalo Therapeutics, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
13
States / cities
Hialeah, Florida • New Port Richey, Florida • Atlanta, Georgia + 9 more
Source: ClinicalTrials.gov public record
Updated Feb 25, 2024 · Synced Jul 22, 2026, 5:49 AM EDT
Terminated Not applicable Interventional

Short Versus Long Interval to Ileostomy Reversal After Ileal Pouch Surgery

NCT03587519
View directory record Official record
Conditions
Ulcerative Colitis, Ileal Pouch, Ileostomy - Stoma
Interventions
Early, Late
Procedure
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 64 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
8
States / cities
Los Angeles, California • Aurora, Colorado • Chicago, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 3, 2022 · Synced Jul 22, 2026, 5:49 AM EDT
Withdrawn Not applicable Interventional

Fiber Use in Pediatric Short Bowel Syndrome

NCT00922805
View directory record Official record
Conditions
Short Bowel Syndrome
Interventions
guar gum
Dietary Supplement
Lead sponsor
Arkansas Children's Hospital Research Institute
Other
Eligibility
2 Weeks to 1 Year
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Jan 14, 2014 · Synced Jul 22, 2026, 5:49 AM EDT
No Longer Available No phase listed Expanded access

Use of Omega 3 Oil Emulsion for Parenteral Nutrition Associated Cholestasis

NCT02148146
View directory record Official record
Conditions
Cholestasis
Interventions
Omegaven
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
Up to 18 Years
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
2
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jan 11, 2021 · Synced Jul 22, 2026, 5:49 AM EDT
Recruiting Not applicable Interventional

A 90 Day, Phase 3,Open Labeled Exploratory Study of RELiZORB

NCT03530852
View directory record Official record
Conditions
Short Bowel Syndrome, Malabsorption
Interventions
Relizorb
Device
Lead sponsor
Boston Children's Hospital
Other
Eligibility
2 Years to 18 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2028
U.S. locations
2
States / cities
Los Angeles, California • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 5, 2026 · Synced Jul 22, 2026, 5:49 AM EDT
Active, not recruiting Phase 2 Interventional

Testing Nivolumab and Ipilimumab With Short-Course Radiation in Locally Advanced Rectal Cancer

NCT04751370
View directory record Official record
Conditions
Locally Advanced Rectal Adenocarcinoma, Stage II Rectal Cancer AJCC v8, Stage III Rectal Cancer AJCC v8
Interventions
Computed Tomography, Ipilimumab, Magnetic Resonance Imaging, Nivolumab, Radiation Therapy, Sigmoidoscopy, Total Mesorectal Excision
Procedure · Biological · Radiation
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
214
States / cities
Mobile, Alabama • Anchorage, Alaska • Phoenix, Arizona + 146 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Jul 22, 2026, 5:49 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Enteral Glutamine in Reducing Bloodstream Infections in Short Bowel Syndrome Infants

NCT01576003
View directory record Official record
Conditions
Bloodstream Infections, Short Bowel Syndrome, Development, Nutrition, Biological Markers
Interventions
Glutamine, L-alanine
Drug · Dietary Supplement
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
6 Weeks to 12 Months
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2015
U.S. locations
2
States / cities
Ann Arbor, Michigan • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 10, 2020 · Synced Jul 22, 2026, 5:49 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy Study of Teduglutide in Subjects With Short Bowel Syndrome

NCT00081458
View directory record Official record
Conditions
Short Bowel Syndrome
Interventions
Placebo, Teduglutide 0.05 mg/kg/d, Teduglutide 0.1 mg/kg/d
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years and older
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
14
States / cities
Scottsdale, Arizona • Washington D.C., District of Columbia • Atlanta, Georgia + 11 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2021 · Synced Jul 22, 2026, 5:49 AM EDT
Completed Phase 2 Interventional Results available

Omegaven® in the Treatment of Parenteral Nutrition (PN) Induced Liver Injury

NCT01845116
View directory record Official record
Conditions
Total Parenteral Nutrition-induced Cholestasis
Interventions
Omegaven®
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
4 Weeks to 18 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2020
U.S. locations
1
States / cities
Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 22, 2022 · Synced Jul 22, 2026, 5:49 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity of Rotavirus Vaccine (RotaTeq(R)) in Infants With Short Bowel Syndrome

NCT00767364
View directory record Official record
Conditions
Short Bowel Syndrome
Interventions
Oral, live, pentavalent rotavirus vaccine; RotaTeq(R)
Biological
Lead sponsor
Children's Hospital of Michigan
Other
Eligibility
6 Weeks to 18 Months
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2013
U.S. locations
3
States / cities
Boston, Massachusetts • Detroit, Michigan • Royal Oak, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 12, 2014 · Synced Jul 22, 2026, 5:49 AM EDT
Completed Phase 2 Interventional

Diet/Growth Factor Mechanisms of Gut Adaptation

NCT00067860
View directory record Official record
Conditions
Short Bowel Syndrome
Interventions
recombinant human growth hormone, diet modification
Drug · Behavioral
Lead sponsor
Emory University
Other
Eligibility
18 Years to 80 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2006
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated May 15, 2016 · Synced Jul 22, 2026, 5:49 AM EDT
Recruiting Phase 2 Interventional

A Phase I-II Study to Test the Safety and Efficacy of PD1 (AB122) and Adenosine Receptor (AB928) Antagonists With Chemotherapy After Short-Course Radiation for Rectal Cancer.

NCT05024097
View directory record Official record
Conditions
Rectal Cancer
Interventions
Etrumadenant (AB928), Radiation therapy, FOLFOX regimen, Zimberelimab (AB122)
Drug · Radiation
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 90 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2030
U.S. locations
3
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 26, 2025 · Synced Jul 22, 2026, 5:49 AM EDT
Completed Not applicable Interventional

Sham Feeding Post-operative Infants

NCT03350022
View directory record Official record
Conditions
Newborn Morbidity, Oral Aversion, Gastroschisis, Bowel Obstruction, Short Bowel Syndrome
Interventions
Sham Feeding
Procedure
Lead sponsor
Le Bonheur Children's Hospital
Other
Eligibility
Up to 2 Years
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 19, 2020 · Synced Jul 22, 2026, 5:49 AM EDT
Completed Not applicable Interventional

Assessing Metabolic and Sleep Consequences of Overnight Home Parenteral Nutrition

NCT04743960
View directory record Official record
Conditions
Feeding Patterns, Sleep, Glucose Intolerance, Short Bowel Syndrome
Interventions
Time-of-day of parenteral nutrition provision
Dietary Supplement
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 79 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 24, 2025 · Synced Jul 22, 2026, 5:49 AM EDT